Shares of ResMed Inc. RMD inched 0.56% higher to $233.88 Thursday, on what proved to be an all-around mixed trading session ...

Goldman Sachs has a buy rating and $36.20 price target on Woolworths' shares. Sign Up for Take Stock Investment news, stock ...

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shares of ResMed Inc. RMD slid 0.30% to $233.18 Friday, on what proved to be an all-around grim trading session for the stock ...

During five years of share price growth, ResMed achieved compound earnings per share (EPS) growth of 21% per year. This EPS growth is higher than the 8% average annual increase in the share price.

These 2 ASX shares are set to deliver a strong set of earnings in the next quarter according to experts. Let's dive in.

Though Apple's expensive headset was been praised for its cutting-edge technology, the device is expensive and hasn't yet ...

CorMedix is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The ...

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Peter C. Farrell, Chairman Emeritus and Director at ResMed Inc . (NYSE:RMD), recently sold shares of the company in a transaction dated December 4, 2024. ResMed, with a market ...